Economic Considerations in the Development of New Treatments for Neuromuscular Diseases Beaver Hollow Conference Center, Java Center, NY September 21-23, 2014

Final Agenda

Saturday, September 20, 2014			
Arrival at Beaver Hollow for those attending ancillary workshops/meetings on Sunday			
7:00 – 8:00 pm	Dinner for those attending ancillar	y meetings on Sunday	Mallard Room
Day 1: Sunday, September 21, 2014			
7:00 – 8:00 am	Buffet Breakfast		
8:00 am – 5:00 pm ANCILLARY MEETINGS/WORKSHOPS (MULTICENTER INVESTIGATOR GROUPS (OPEN TO ALL ATTENDEES; TRAINEES ENCOURAGED TO PARTICIPATE)			
8:00 – 9:00 am	Methotrexate Ancillary Meeting	Richard Barohn, MD and Ms. Laura Herbelin	Maple Room
9:00 – 10:00 am	Rasagiline Ancillary Meeting	Richard Barohn, MD and Ms. Laura Herbelin	Maple Room
10:00 – 11:00 am	FOR-DMD Ancillary Meeting	Robert Griggs, MD and Katie Bushby, MD	The Aud
11:00 am – 12:00 pm	The International IBM Consortium Genetic Study Ancillary Meeting	Pedro Machado, MD and Michael Hanna, MD	
12:00 – 1:30 pm	:00 – 1:30 pm LUNCH FOR ANCILLARY STUDY PARTICIPANTS		
12:00 – 1:30 pm	MSG Executive Committee Meeting Photos will be taken of Executive Committee Members		Drake Room
1:30 – 2:30 pm	NeuroNEXT: Rituxamab in MG Study	Richard Nowak, MD	Maple Room
2:30 – 3:00 pm	Poster Session Set-Up		Lodge
2:30 – 3:30 pm	Arimoclomol FDA Study	Mazen Dimachkie, MD	Maple Room
2:30 – 3:30 pm	<u>Investigating</u> <u>Pompe Prevalence in</u> <u>NE</u> uromuscular <u>Medicine</u> <u>Academic</u> Practices (IPANEMA Study)	Tahseen Mozaffar, MD	Hemlock Room

Economic Considerations in the Development of New Treatments for Neuromuscular Diseases Beaver Hollow Conference Center, Java Center, NY September 21-23, 2014

Final Agenda

Day 1: Sunday, September 21, 2014 (continued)			
3:30 – 4:40 pm	UPDATE ON CURRENT/PLANNED MSG TRIALS (ALL MSG MEETING ATTENDEES ENCOURAGED TO ATTEND)		
3:30 – 3:40 pm	FOR – DMD Study	Robert Griggs, MD (University of Rochester)	
3:40 – 3:50 pm	Arimoclomol IBM (Orphazyme)	Mazen Dimachkie, MD (Kansas University Medical Center)	
3:50 – 4:00 pm	Methotrexate Study	Laura Herbelin/Richard Barohn, MD (Kansas University Medical Center)	
4:00 – 4:10 pm	Rasagiline Study	Richard Barohn, MD (Kansas University Medical Center)	
4:10 – 4:20 pm	International IBM Consortium	Michael Hanna, MD/Pedro Machado, MD University College London	
4:20 – 4:30 pm	International Neuropathy Consortium	Michael Shy, MD University of Iowa	
4:30 – 4:40 pm	<u>I</u> nvestigating <u>P</u> ompe Prev <u>alence in</u> <u>NE</u> uromuscular <u>M</u> edicine <u>A</u> cademic Practices (IPANEMA Study)	Tahseen Mozaffar, MD (University of California, Irvine)	
4:40 – 5:20 PM	Break		
5:20 – 6:00 PM	BRIEF PRESENTATIONS AND POSTER SESSION I Moderators: Ted Burns, MD (University of Virginia) and Gil Wolfe, MD (University at Buffalo)		
5:20 – 5:30 PM	Complications of Pregnancy in Myotonic Dystrophy	Nicholas Johnson, MD (University of Utah)	
5:30 – 5:40 PM	MRI Quantification of Fixed Myopathy in Hypokalaemic Periodic Paralysis Identifies Potential Therapeutic Window	Jasper Morrow, FRACP (University College London)	
5:40 – 5:50 PM	Combined N-of-1 Trials Mexiletine vs. Placebo in Non-Dystrophic Myotonia using a Bayesian Approach	Bas Stunnenberg, MD (University Nijmegen Medical Center)	

Economic Considerations in the Development of New Treatments for Neuromuscular Diseases Beaver Hollow Conference Center, Java Center, NY September 21-23, 2014

Final Agenda

Day 1: Sunday, September 21, 2014 (continued)		
5:50 – 7:00 PM	POSTER SESSION WITH HORS D'OEUVRES & CASH BAR	Fireside/Lodge
7:00 - 8:00 PM	DINNER	Mallard/Lodge
8:00 PM	Keynote Speaker	Fireside
	W. King Engel, MD	
	University of Southern California	
	Historical Perspectives on Evolution of	
	Diagnosis and Management of Muscle Disorders During his Career	

Day 2: Monday, September 22, 2014		
7:00 – 8:00 AM	BREAKFAST	Mallard/Lodge
7:00 – 8:00 AM	Informal Breakfast Seminar for New Members/Guests (open to all)	Drake Room
	Moderators: Richard Barohn and Robert C. Griggs	
8:00 – 8:10 AM	WELCOME/GENERAL SESSION	Fireside Room
	Robert C. Griggs (University of Rochester), Mazen Dimachkie (Kansas University Medical Center), Jaya Trivedi (UT Southwestern) and Tahseen Mozaffar (UC Irvine)	
8:10 – 11:30 AM	ECONOMIC CONSIDERATIONS IN THE DEVELOPMENT OF NEW TREATMENTS FOR NEUROMUSCULAR DISEASES SESSION I: Challenges in Developing and Running Clinical Trials in Rare Diseases Moderator: Karl Kieburtz, MD, MPH	
8:10 – 8:40 AM	Evidentiary Criteria for Accelerated Approval of New Medicines: Cataloging FDA's Flexibility in Subpart H Approvals	Frank Sasinowski, MS, MPH, JD (Hyman, Phelps and McNamara)

Economic Considerations in the Development of New Treatments for Neuromuscular Diseases Beaver Hollow Conference Center, Java Center, NY September 21-23, 2014

Final Agenda

	Day 2: Monday, September 22, 2014 (Cor	ntinued)
8:40 – 9:10 AM	Patient-Reported Outcomes in Randomized Clinical Trials	Ira Shoulson, MD (Georgetown)
9:10 – 9:40 AM		
9:40 – 10:00 AM	Break	
10:00 – 10:30 AM	Funding New Investigators: the Role of the CTSAs	Karl Kieburtz, MD (University of Rochester)
10:30 – 11:00 AM	Panel Discussion	Mr. Sasinowski, Drs. Shoulson and Kieburtz
11:00 – 11:30 AM	Break/Group Photo	Pool Area or The Aud/Lodge
11:30 – 12:30 PM	MINI-SYMPOSIUM ON POMPE DISEASE	
11:30 AM – 12:00 PM	Advances in Therapeutics for Pompe	Loren Pena, MD, PhD
	Disease	(Duke University)
12:00 – 12:30 PM	Perspectives on Gene Therapy for Pompe	Barry Byrne, MD, PhD
	Disease	(University of Florida)
12:30 – 1:30 PM	Lunch	Mallard/Lodge
1:30 – 2:30 PM	CLINICAL TRIAL DEVELOPMENT: DIFFICULTIES OF ENROLLING IN RARE DISEASES	
1:30 – 2:00 PM	EPITOME Study in Ocular MG	Michael Benatar, MD, DPHIL (University of Miami)
2:00 – 2:30 PM	Burden of Illness in DMD	Kate Bushby, MD (Newcastle University)
2:30 - 3:30 PM	UPDATES FROM THE NIH	
2:30 – 2:50 PM	NeuroNext	Richard Barohn, MD (Kansas University Medical Center)
2:50 – 3:10 PM	NIAMS	Glen Nuckolls, PhD (NIH/NIAMS)
3:10 – 3:30 PM	NINDS	John Porter, PhD (NIH/NINDS)
3:30 – 4:00 PM	Break	

Economic Considerations in the Development of New Treatments for Neuromuscular Diseases Beaver Hollow Conference Center, Java Center, NY September 21-23, 2014

Final Agenda

Day 2: Monday, September 22, 2014 (Continued)			
4:00 – 5:30 PM	CURRENT STATUS OF IMAGING AS BIOMARKER FOR NEUROMUSCULAR DISORDERS		
4:00 – 4:20 PM	MRI in aiding clinical diagnosis of Muscle Diseases	Volker Straub, M (Newcastle Univ	•
4:20 – 5:00 PM	MRI in experimental muscle therapeutics	Tracey Willis, Ph (Newcastle Univ	
5:00 – 5:20 PM	Muscle Ultrasound in the Evaluation of Neuromuscular Diseases	Craig Zaidman, MD (Washington University)	
5:20 – 5:35 PM	Panel Discussion	Drs. Straub, Will	is and Zaidman
5:35 – 6:00 PM	Break/Free Time/Informal Discussion		
6:00 – 7:30 PM	BRIEF PRESENTATIONS AND POSTER S Moderators: Ted Burns, MD (University of (University at Buffalo)		l Wolfe, MD
6:00 – 6:10 PM	Distinct Autoantibodies Associate with Specific Histological Abnormalities in Dermatomyositis	lago Pinal-Fernandez, MD (Johns Hopkins)	
6:10 – 6:20 PM	Investigating Pathogenic B Cell Populations in MuSK Myasthenia Gravis	Richard Nowak, MD, MS (Yale University)	
6:20 – 6:30 PM	Transcriptome Profiling Identifies Key Differences Between patients with Recessive or Dominant Negative Mutations in Collagen VI Related Myopathies	Russell Butterfield, MD (University of Utah)	
6:30 – 7:30 PM	POSTER SESSION WITH HORS D'OEUVRES & CASH BAR		Fireside/Lodge
7:30 – 8:30 PM	DINNER		Mallard/Lodge
8:30 PM	Keynote Speaker Valerie Askanas, MD, PhD University of Southern California Overview of IBM advances and future directions		Fireside Room

Economic Considerations in the Development of New Treatments for Neuromuscular Diseases Beaver Hollow Conference Center, Java Center, NY September 21-23, 2014

Final Agenda

	Day 3: Tuesday, September 23, 20	<u>14</u>	
7:00 – 9:00 AM	Checkout (Those staying at the Hampton Inn should bring their luggage to Beaver Hollow. Space will be available near the front desk for luggage storage.)		
7:00 - 8:00 AM	Buffet Breakfast Mallard/Lodge		
8:00 – 8:10 AM	MSG Status Report	Robert Griggs, MD and Rabi Tawil, MD (University of Rochester)	
	Nominations	Robert Griggs, MD (University of Rochester)	
8:10 – 11:30 AM	ECONOMIC CONSIDERATIONS IN THE DEVELOPMENT OF NEW TREATMENTS FOR NEUROMUSCULAR DISEASES		
	SESSION II: Molecular Discoveries with Implications for the Development of Novel Therapies		
	Moderator: Charles Thornton, MD		
8:10 – 8:40 AM	Development of Novel Therapies in Musculoskeletal Diseases	Edward Kaye, MD (Sarepta Therapeutics)	
8:40 – 9:10 AM	Challenges of Setting Up a Pivotal Clinical Trial in Muscle Diseases	Brian Tseng, MD, PhD (Novartis)	
9:10 – 9:20 AM	Discussion	(140 vario)	
9:20 – 9:30 AM	Break		
9:30 – 9:50 AM	Targeting Mitochondrial Oxidative Stress to Improve Aging Skeletal Muscle Function	David Marcinek, PhD (University of Washington)	
9:50 - 10:20 AM	LESSON LEARNED FROM THE C9ORF72		
9:50 – 10:20 AM	Modeling the Disease in iPS Cells and the Lessons Learned	Robert H. Baloh, MD, PhD (Cedars Sinai)	
10:20 – 11:20 AM	Updates		
10:20 – 10:40 AM	FSHD	Silvere van der Maarel, MD (Leiden University)	
10:40 – 11:00 AM	Congenital Muscular Dystrophies: A Translational Update	Carsten Bönnemann, MD PhD (NIH/NINDS)	
11:00 – 11:20 AM	Myofibrillar Myopathies	Ami Mankodi, MD (NIH/Neurogenetics Branch)	
11:20 – 11:40 AM	HYP-HOP Study	Robert Griggs, MD (University of Rochester)	

Economic Considerations in the Development of New Treatments for Neuromuscular Diseases Beaver Hollow Conference Center, Java Center, NY September 21-23, 2014

Final Agenda

Day 3: Tuesday, September 23, 2014 (continued)		
11:40 AM - 12:00 Noon	Discussion	Drs. van der Maarel,
		Bönnemmann and Mankodi
12:00 – 1:00 PM	Lunch and Departures	Mallard/Lodge